- Email: [email protected]
4925831 Aminoalkyl naphthalenediols as host resistance enhancers against viral infection
New Patents tiaUy monospecific antibody or antibody fragment which specifically binds to at least one leukocyte cell type, conjugated to at least one therapeutic antimicrobial agent. A method of treatment of an infectious lesion comprises injecting a mammal parenterally with an effective amount for therapy of the above anti-leukocyte therapeutic conjugate.
4925661 TARGET-SPECIFIC CYTOTOXIC LIPOSOMES Leaf Huang The A fragment of the diphtheria toxin (DTA) was encapsulated in pH-sensitive liposomes. This novel reagent is extremely cytotoxic to cells expressing surface antigen which is recognized by the immunoliposome. The reagent is not toxic to cells which do not express the antigen. Thus, this reagent, or others similarly prepared represent potential anticancer reagents.
ix
more covalently attached trisaccharide, sialic acid right arrowgalactose right arrowNacetylglucosamine right arrow(SA right arrowGal right arrowGIcNac right arrow), or tetrasaccharide (SA right arrowGal right arrowGlcNAc right arrowGlcNAc right arrow) moieties. The method can be applied to any natural or recombinant protein possessing asparagine-linked oligosaccharides or to any non-glycosylated protein that can be chemically or enzymatically derivatized with the appropriate carbohydrate units. Following injection into an animal, the modified glycoproteins are protected from premature clearance by cells of the liver and reticulo-endothelial system which recognize and rapidly internalize circulating glycoproteins with carbohydrate chains containing terminal Gal, GlnNAc, fucose or mannose residues. The method can also be used to mask antigenic determinants on foreign proteins which would otherwise produce an immune response or to target a protein for recognition by sugar-specific cell surface receptors.
4925831 4925662 ANTI-TUMOR SUBSTANCE AND PROCESS FOR PRODUCING THE SAME
AMINOALKYL N A P H T H A L E N E D I O L S AS H O S T RESISTANCE ENHANCERS AGAINST VIRAL INFECTION Philippe L Durette assigned to Merck & Co Inc
Yoshiharu Oguchi, Koichi Niimura, Takayoshi Fujii, Masahiko Fujii, Kenichi Matsunaga, Chikao Yoshikumi, Tokyo, Japan assigned to Kureha Kagaku Kogyo Kabushiki Kaisha Disclosed herein are an anti-tumor substance obtained by bonding an anti-tumor agent to human immunoglobulin, and a process for producing the same.
Disclosed are s p e c i f i c aminoalkyl naphthalenediol derivatives that enhance natural human host resistance to viral infectious organisms and particularly AIDS-related viruses. Such agents are also administered prophylactically to individuals whose resistance to infection has been specifically immunocompromised by an AIDs-related (HIV) virus.
4925796
4925919
METHOD FOR ENHANCING GLYCOPROTEIN STABILITY
PURIFIED INTERLEUKIN 2
Michel L E Bergh, S Catherine Hubbard, James R Rasmussen assigned to Massachusetts Institute of Technology A method for modifying eukaryotic and prokaryotic proteins to extend their in vivo circulatory lifetimes. In the preferred embodiment, enzymatic and/or chemical treatments are used to produce a modified protein carrying one or
Rolan Mertelsmann, Kar Welte, Salvatore Venuta Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal human blood cells by (NH4)2SO4-precipitation, ion-exchange
4925661 TARGET-SPECIFIC CYTOTOXIC LIPOSOMES Leaf Huang The A fragment of the diphtheria toxin (DTA) was encapsulated in pH-sensitive liposomes. This novel reagent is extremely cytotoxic to cells expressing surface antigen which is recognized by the immunoliposome. The reagent is not toxic to cells which do not express the antigen. Thus, this reagent, or others similarly prepared represent potential anticancer reagents.
ix
more covalently attached trisaccharide, sialic acid right arrowgalactose right arrowNacetylglucosamine right arrow(SA right arrowGal right arrowGIcNac right arrow), or tetrasaccharide (SA right arrowGal right arrowGlcNAc right arrowGlcNAc right arrow) moieties. The method can be applied to any natural or recombinant protein possessing asparagine-linked oligosaccharides or to any non-glycosylated protein that can be chemically or enzymatically derivatized with the appropriate carbohydrate units. Following injection into an animal, the modified glycoproteins are protected from premature clearance by cells of the liver and reticulo-endothelial system which recognize and rapidly internalize circulating glycoproteins with carbohydrate chains containing terminal Gal, GlnNAc, fucose or mannose residues. The method can also be used to mask antigenic determinants on foreign proteins which would otherwise produce an immune response or to target a protein for recognition by sugar-specific cell surface receptors.
4925831 4925662 ANTI-TUMOR SUBSTANCE AND PROCESS FOR PRODUCING THE SAME
AMINOALKYL N A P H T H A L E N E D I O L S AS H O S T RESISTANCE ENHANCERS AGAINST VIRAL INFECTION Philippe L Durette assigned to Merck & Co Inc
Yoshiharu Oguchi, Koichi Niimura, Takayoshi Fujii, Masahiko Fujii, Kenichi Matsunaga, Chikao Yoshikumi, Tokyo, Japan assigned to Kureha Kagaku Kogyo Kabushiki Kaisha Disclosed herein are an anti-tumor substance obtained by bonding an anti-tumor agent to human immunoglobulin, and a process for producing the same.
Disclosed are s p e c i f i c aminoalkyl naphthalenediol derivatives that enhance natural human host resistance to viral infectious organisms and particularly AIDS-related viruses. Such agents are also administered prophylactically to individuals whose resistance to infection has been specifically immunocompromised by an AIDs-related (HIV) virus.
4925796
4925919
METHOD FOR ENHANCING GLYCOPROTEIN STABILITY
PURIFIED INTERLEUKIN 2
Michel L E Bergh, S Catherine Hubbard, James R Rasmussen assigned to Massachusetts Institute of Technology A method for modifying eukaryotic and prokaryotic proteins to extend their in vivo circulatory lifetimes. In the preferred embodiment, enzymatic and/or chemical treatments are used to produce a modified protein carrying one or
Rolan Mertelsmann, Kar Welte, Salvatore Venuta Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal human blood cells by (NH4)2SO4-precipitation, ion-exchange